A novel therapeutic vaccine approach, targeting RANKL, prevents bone destruction in bone-related disorders

J Bone Miner Metab. 2002;20(5):266-8. doi: 10.1007/s007740200038.
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy
  • Bone Demineralization, Pathologic / prevention & control
  • Bone Diseases / physiopathology
  • Bone Diseases / prevention & control*
  • Bone Remodeling / physiology
  • Bone Resorption / prevention & control
  • Carrier Proteins / drug effects
  • Carrier Proteins / immunology*
  • Carrier Proteins / metabolism
  • Glycoproteins / pharmacology
  • Glycoproteins / therapeutic use*
  • Humans
  • Membrane Glycoproteins / drug effects
  • Membrane Glycoproteins / immunology*
  • Membrane Glycoproteins / metabolism
  • Mice
  • NF-kappa B / metabolism
  • Osteoclasts / metabolism
  • Osteoprotegerin
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear / therapeutic use*
  • Receptors, Tumor Necrosis Factor
  • Vaccines / pharmacology
  • Vaccines / therapeutic use*

Substances

  • Carrier Proteins
  • Glycoproteins
  • Membrane Glycoproteins
  • NF-kappa B
  • Osteoprotegerin
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Receptors, Cytoplasmic and Nuclear
  • Receptors, Tumor Necrosis Factor
  • TNFRSF11A protein, human
  • TNFRSF11B protein, human
  • TNFSF11 protein, human
  • Tnfrsf11a protein, mouse
  • Tnfrsf11b protein, mouse
  • Tnfsf11 protein, mouse
  • Vaccines